A systematic review and meta-analysis of serum lipid concentrations in people with Down syndrome.
Adults with Down syndrome show worse lipid profiles, so yearly blood work is essential.
01Research in Context
What this study did
Gastelum Guerrero et al. (2024) pooled 15 earlier studies. They compared lipid blood tests of 671 people with Down syndrome to 898 without.
The team ran a meta-analysis. This means they averaged all results to see the big picture.
What they found
People with Down syndrome had lower good HDL cholesterol and lower total cholesterol. Their triglycerides were higher.
These patterns raise heart-disease risk, so early lipid checks are wise.
How this fits with other research
Jones et al. (1992) saw the same lipid pattern years ago but called it a puzzle. They expected good lipids would explain why Down syndrome patients rarely have heart attacks. The new data keep the puzzle alive.
Ghaziuddin et al. (1996) warned that many medical problems are more common in Down syndrome. The lipid issue is now one more item on that longer checklist.
Stancliffe et al. (2007) tracked midlife adults with Down syndrome and found heart and lung causes top the death list. The 2024 lipid findings give a clear, measurable target to watch.
Why it matters
If you serve adults with Down syndrome, add a fasting lipid panel to their annual labs. Share results with the primary doctor and use them when planning exercise or diet programs. Catching bad numbers early lets you pair behavioral interventions with medical follow-up before bigger heart trouble starts.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Schedule a doctor visit for a fasting lipid panel if your client has not had one in the past year.
02At a glance
03Original abstract
BACKGROUND: Down syndrome (DS) is the most prevalent chromosomal disorder, being the leading cause of intellectual disability. The increased life expectancy of individuals with DS has led to a shift in the incidence of non-communicable chronic diseases, resulting in new concerns, particularly cardiovascular disease (CVD) and Alzheimer's disease. This study aimed to analyse the blood lipid profile of a large DS cohort to establish a baseline for evaluating health risk parameters. METHODS: A comprehensive literature search was conducted on PubMed and Virtual Health Library databases to identify original articles published before July 2022. Selected studies were included in the meta-analysis. RESULTS: Fifteen studies reporting serum lipid levels in individuals with DS were incorporated into the analysis. The meta-analysis used the means and standard deviations extracted from the selected studies. The analysis encompassed 671 participants in the DS group and 898 euploid controls. The results indicated significant differences in total cholesterol [C] (mean difference [MD]: -3.34; CI: 95%: -4.94 to -1.73; P < 0.0001), HDL-C (MD: -3.39; CI: 95%: -6.72 to -0.06; P = 0.05) and triglycerides (MD: 21.48; CI: 95%: 9.32 to 33.65; P = 0.0005) levels between individuals with DS and their control counterparts. CONCLUSIONS: Individuals with DS have less favourable blood lipid concentrations than their controls, particularly HDL-C, triglycerides, and total-C, even when grouped by age. These findings underscore the importance of closer monitoring of lipid profiles in people with DS and the necessity for specific cut-offs for this population, considering the risk for ischemic heart and Alzheimer's diseases.
Journal of intellectual disability research : JIDR, 2024 · doi:10.1111/jir.13128